NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

The marketing of a "me too" drug

Posted By



John Mack, on his terrific Pharma Marketing Blog, gives us a pharma marketing perspective on the creation of an Omega-3 fatty acid prescription drug. Excerpt:

“The pharmaceutical industry is often criticized for developing new Rx drugs having little value over current medications. Such drugs are called ‘me-too’ drugs because of their similarity to existing Rx drugs. Glaxo has now taken this to a completely NEW level: developing an Rx drug that is a ‘me-too’ of existing over-the-counter dietary supplements. I am talking about LOVAZA, aka omega-3-acid esters approved by the FDA for the treatment of high triglycerides.”

Mack goes on to do a cost and ingredient comparison, and explores what might be the clinical reality of the introduction of this new prescription drug. Read his entire blog entry.

Here’s an ad for LOVAZA, which Mack cut out of this week’s Newsweek Magazine:


You might also like

Comments (2)

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Gregory D. Pawelski

January 21, 2010 at 8:12 pm

The big problem with ‘me-too’ drugs is that they are chemically very similar to other drugs already available, yet they are marketed as if they were important new breakthroughs, with very high prices. Many new, expensive ‘me-too’ drugs are not necessarily better than older and less expensive drugs. Most of the time they are compared with placebos and not older drug comparisions.